Clinical trial
Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of…
NCT00114686 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00114686 |
|---|---|
| Title | Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder |
| Official title | A Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) Versus Placebo as Adjunct Therapy With Mood Stabilizers (Lithium or Divalproex) for the Treatment of Alcohol Dependence in Patients With… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bipolar I Disorder, Alcohol Dependence |
| Intervention type | Drug |
| Interventions | Quetiapine fumarate, lithium, divalproex |
| Enrollment | 350 |
| Start date | Jan 1, 2006 |
| Completion | Apr 1, 2007 |
| First posted | Jun 17, 2005 |
| Last update posted | Jan 4, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: